Breakthrough research at ABUAD-MSH offers hope for early osteoarthritis intervention

A team of researchers at Afe Babalola University Multi-System Hospital (ABUAD-MSH), has achieved a breakthrough in orthopaedic surgery in addressing the burden of osteoarthritis in Nigeria. By utilising advanced research, innovative treatment methods, and comprehensive care approaches, the health institution has moved beyond traditional diagnostic techniques.

The groundbreaking research which has significant implications for osteoporosis diagnosis and management,  lays a scientific foundation for the development of targeted therapies for osteoporosis patients and preventing its progression in the country.

Osteoarthritis is an under-diagnosed and under-treated degenerative joint disease, characterized by the gradual breakdown of cartilage, causes significant pain, stiffness, and reduced mobility, making it a leading cause of disability among older adults.

Led by the Deputy Medical Director, ABUAD-MSH, Dr. Akinola Akinmade,  the research team investigated the relationship between the use of novel non-radiation biomarkers and the severity of knee osteoarthritis in  patients. Their findings revealed that the high levels of the biomarker could be an important marker for detecting the disease early.

In a statement, “Advancing Orthopaedic Care: Tackling Osteoarthritis Through Innovation and Research at Afe Babalola University Multi-System Hospital”,  Akinmade, who is one of the university’s top orthopaedic surgeons, said the research has important benefits for doctors and patients, noting that identifying osteoarthritis early through biomarker testing allows for prompt treatment, it can help postpone more invasive options like joint replacement surgery.

“ABUAD-MSH has established itself as a hub for cutting-edge research on osteoarthritis. While traditional diagnosis of the condition is based on weight bearing plain X-rays, Dr. Akinmade and his team have researched the use of non-radiation linked biomarkers like serum cartilage oligomeric matrix protein (COMP) as a potential biomarker for early detection of knee osteoarthritis.

“This research, conducted in collaboration with renowned experts in the field, offers a promising avenue for diagnosing the disease in its early stages, before irreversible joint damage occurs. The research involved a cohort of patients with varying degrees of knee osteoarthritis and examined the correlation between COMP levels and disease severity. The findings revealed that elevated COMP levels are associated with advanced cartilage degradation, making it a reliable indicator of disease progression.

“This research has significant implications for both clinicians and patients. Early detection of osteoarthritis through biomarker analysis allows for timely intervention, potentially delaying the need for surgical procedures such as joint replacement. Moreover, it provides a scientific basis for developing targeted therapies aimed at preserving cartilage and preventing further damage.”

Further, Akinmade argued that by detecting osteoarthritis early, clinicians can implement interventions to slow disease progression, preserve joint function, and improve patients’ quality of life.

“As the population ages, osteoarthritis has become increasingly prevalent, particularly in low- and middle-income countries. In Nigeria, where access to specialised healthcare is limited for many, the condition poses unique challenges. It is estimated that over 10 percent of the global population aged 60 and above suffers from symptomatic osteoarthritis, with the knee and hip joints being the most commonly affected.

“This research underscores ABUAD-MSH’s commitment to advancing medical knowledge and improving patient care. By pioneering innovative diagnostic approaches, the institution is making significant contributions to the field of rheumatology and improving the quality of life for individuals suffering from osteoarthritis.

Noting that since its inception, ABUAD-MSH has prioritized excellence in healthcare delivery, with the aim of becoming a leading center for medical innovation in Nigeria, Akinmade explained that the impact of osteoarthritis extends beyond physical pain.

“This research underscores the hospital’s commitment to advancing evidence-based medicine and contributing to global knowledge on degenerative joint diseases. At ABUAD-MSH, a dedicated effort has been made to address the burden of osteoarthritis through advanced research, innovative treatment methods, and comprehensive care. The hospital’s achievements in the management of osteoarthritis, highlight the transformative impact of a multidisciplinary approach to healthcare.

“For elderly individuals, the condition often limits independence, reduces quality of life, and increases the risk of comorbidities such as depression and cardiovascular disease. Addressing this condition requires a holistic approach that integrates early diagnosis, effective management strategies, and accessible care.

Further, Akinmade stated that the institution already provides a wide range of treatment options from non-surgical to for osteoarthritis, designed to address the diverse needs of its patients

“ABUAD-MSH is equipped with state-of-the-art facilities that enable the delivery of world-class orthopaedic care. The hospital’s focus on continuous innovation has led to the integration of cutting-edge technologies, such as advanced imaging systems and robotic surgical tools. These investments not only enhance diagnostic accuracy but also improve surgical outcomes.

“The hospital’s commitment to infrastructure development is further reflected in its efforts to provide equitable access to healthcare. Recognizing the economic challenges faced by many patients, ABUAD-MSH has introduced subsidized treatment programs to ensure that quality care remains accessible to all segments of the population.”

On the role of research in public health, he emphasised that integration of research into clinical practice by the team at ABUAD-MSH demonstrates the critical role of evidence-based medicine in addressing public health challenges.

“The hospital’s focus on research highlights the potential of locally conducted studies to generate solutions that are both effective and contextually relevant. By exploring innovative diagnostic tools, such as biomarkers, and evaluating the effectiveness of various treatment modalities, ABUAD-MSH is contributing to the development of a comprehensive framework for osteoarthritis management in Nigeria and beyond.

“ABUAD-MSH’s orthopaedic programme is not limited to osteoarthritis. The hospital offers a broad spectrum of services, including trauma care, spinal surgeries, and the management of congenital musculoskeletal disorders. This comprehensive approach ensures that patients receive holistic care, regardless of the complexity of their conditions.”

He said efforts are also underway to expand the hospital’s capacity for orthopaedic research and training. By fostering an environment of innovation and collaboration, ABUAD-MSH aims to produce the next generation of healthcare leaders who will drive advancements in orthopaedics.

“As ABUAD-MSH continues to grow, the hospital remains committed to its mission of delivering world-class care while addressing the unique healthcare needs of the Nigerian population. The hospital’s plans to scale up its research and clinical programs, particularly in the area of osteoarthritis, reflect its vision of becoming a global leader in healthcare innovation,” Akinmade stated.